Efficacy and Safety In Poorly Controlled Type 2 Diabetics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00044460|
Recruitment Status : Completed
First Posted : August 30, 2002
Last Update Posted : October 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Drug: rosiglitazone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||142 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus|
|Actual Study Start Date :||May 2002|
|Actual Primary Completion Date :||April 10, 2003|
|Actual Study Completion Date :||April 10, 2003|
- Change in HbA1c from baseline to Week 24.
- Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00044460
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|